| Summary of significant segment expenses |
| | | | | | | | | Three Months Ended March 31, | (In thousands) | | 2026 | | 2025 | Viatris collaboration agreement | | $ | 17,699 | | $ | 15,388 | Total revenue | | | 17,699 | | | 15,388 | | | | | | | | Employee-related (Research and development) 1 | | | 2,447 | | | 3,931 | External-related (Research and development) | | | 1,952 | | | 5,565 | Facilities and other allocated expenses (Research and development) | | | 803 | | | 886 | Supporting general and administration functions 1 | | | 7,961 | | | 7,258 | Sales and marketing, and medical affairs 1 | | | 6,910 | | | 7,305 | Share-based compensation | | | 3,476 | | | 4,877 | Total recurring operating expenses | | | 23,549 | | | 29,822 | Restructuring expenses (including share-based compensation) | | | 3,633 | | | — | Total operating expenses | | | 27,182 | | | 29,822 | Loss from operations | | | (9,483) | | | (14,434) | Interest expense (non-cash) | | | — | | | (643) | Interest and other income, net | | | 3,013 | | | 939 | Provision for income tax benefit | | | 1,537 | | | 559 | Net loss | | $ | (4,933) | | $ | (13,579) |
1 Excludes share-based compensation
|